AbbVie (ABBV) Other Non-Current Assets (2012 - 2026)
AbbVie (ABBV) posted quarterly Other Non-Current Assets of $10.5 billion for Q1 2026, up 14.62% year-over-year from $9.2 billion in Q1 2025, and down 1.73% quarter-over-quarter from $10.7 billion in Q4 2025.
AbbVie (ABBV) Other Non-Current Assets (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Other Non-Current Assets for 15 consecutive years, with $10.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 14.62% year-over-year to $10.5 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 14.62% YoY), while the FY2025 annual figure was $10.7 billion, up 17.27% from the prior year.
- Other Non-Current Assets fell to $10.5 billion in Q1 2026 per ABBV's latest filing, from $10.7 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $10.7 billion in Q4 2025 and bottomed at $5.0 billion in Q2 2022.
- Historically, Other Non-Current Assets has averaged $7.9 billion across 5 years, with a median of $8.5 billion in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 56.33% — and 2025, when it rose 1.38%.
- AbbVie's Other Non-Current Assets stood at $5.6 billion in 2022, then soared by 52.81% to $8.5 billion in 2023, then advanced by 7.39% to $9.1 billion in 2024, then climbed by 17.27% to $10.7 billion in 2025, then dropped by 1.73% to $10.5 billion in 2026.
- Business Quant data shows ABBV's Other Non-Current Assets at $10.5 billion in Q1 2026, $10.7 billion in Q4 2025, and $9.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.73 Bn |
| Mar 31, 2026 | 10.54 Bn |
| Dec 31, 2025 | 10.72 Bn |
| Sep 30, 2025 | 9.64 Bn |
| Jun 30, 2025 | 9.66 Bn |
| Mar 31, 2025 | 9.19 Bn |
| Dec 31, 2024 | 9.14 Bn |
| Sep 30, 2024 | 8.29 Bn |
| Jun 30, 2024 | 9.20 Bn |
| Mar 31, 2024 | 9.07 Bn |
| Dec 31, 2023 | 8.51 Bn |
| Sep 30, 2023 | 7.09 Bn |
| Jun 30, 2023 | 6.20 Bn |
| Mar 31, 2023 | 5.80 Bn |
| Dec 31, 2022 | 5.57 Bn |
| Sep 30, 2022 | 5.38 Bn |
| Jun 30, 2022 | 5.03 Bn |
| Mar 31, 2022 | 5.08 Bn |
| Dec 31, 2021 | 4.88 Bn |
| Sep 30, 2021 | 4.75 Bn |